Kestra Medical Technologies’ Earnings Call Highlights Rapid Growth

Kestra Medical Technologies Ltd. ((KMTS)) has held its Q3 earnings call. Read on for the main highlights of the call.

Kestra Medical Technologies struck a notably upbeat tone on its latest earnings call, underscoring powerful revenue and prescription growth alongside expanding gross margins and key clinical and regulatory wins. Management balanced this optimism with a candid acknowledgment of widening losses, higher cash burn, and execution risks as the company scales rapidly into a larger commercial footprint.

Revenue Surges and Upgraded Outlook

Kestra reported Q3 revenue of $24.6 million, up 63% year over year, underscoring accelerating adoption of its wearable defibrillator platform. Reflecting this momentum, management raised fiscal 2026 revenue guidance to $93 million, implying 55% growth versus fiscal 2025 and marking the second upward revision since the initial outlook.

Prescription Momentum Signals Market Share Gains

The company accepted more than 5,400 prescriptions in the quarter, representing roughly 58% year-over-year growth and reinforcing its trajectory of strong top-line expansion. Management highlighted this prescription strength as evidence of ongoing market-share gains and new account activation across cardiology centers.

Gross Margins Expand With Line of Sight to 70%+

Gross margin climbed to 52.6% in Q3, improving by about nine percentage points from a year earlier and 200 basis points sequentially. This marked Kestra’s ninth consecutive quarter of sequential gross margin expansion, with management reiterating a multi-year path toward margins above 70% as scale and efficiency improve.

Conversion and Revenue Cycle Management Improve

Kestra’s prescription conversion rate reached approximately 46% in Q3, up from an adjusted 43% in the prior-year quarter and building on steady improvement from 38% in fiscal 2024 and 44% in fiscal 2025. The company credited gains in fill rate, BIN rate, and collections, and is further investing in AI-driven revenue cycle automation to tighten this funnel.

Clinical Evidence and Regulatory Tailwinds

New data from the ACE PAS, billed as the largest real-world prescribed prospective WCD study with more than 21,000 patients, showed low false alarm rates, strong wear-time compliance, and 100% successful conversion of dangerous arrhythmias. Complementing this, the FDA approved an update to the Assure algorithm designed to further reduce false alarms and inappropriate shocks, enhancing clinical appeal.

Strategic Collaboration and Product Expansion

Kestra announced an exclusive collaboration with BioBeat Technologies, including a $5 million equity stake, to integrate cuffless ambulatory blood pressure monitoring into the Assure suite. The company noted that 72% of ACE PAS patients were hypertensive, positioning this capability as highly relevant for future product differentiation and broader patient management.

Market Access Wins Strengthen Reimbursement Profile

On the payer front, Kestra became an approved provider for Florida managed Medicaid and signed contracts with two of the state’s four largest managed Medicaid plans. It was also added to the Federal Supply Schedule for the U.S. Department of Veterans Affairs, while Medicare monthly reimbursement rose 2% to $3,589, collectively improving revenue-per-fit and access.

Capital Position Supports Growth Investments

The company ended January with $291 million in cash and equivalents, bolstered by proceeds from a December equity offering and a recently completed shelf registration. Management emphasized that Kestra remains well-capitalized to fund ongoing commercial expansion, R&D, and infrastructure, despite elevated operating losses and CapEx.

Expanding Commercial Footprint

Kestra closed calendar 2025 with roughly 100 active sales territories and is tracking toward about 130 by the end of the fiscal year in April. This accelerated expansion is intended to broaden geographic coverage and deepen physician engagement, setting up a larger revenue base but increasing near-term spending.

Widening Losses Reflect Heavy Investment

GAAP net loss widened to $34.2 million in Q3 from $21.8 million a year earlier, while adjusted EBITDA loss increased to $21.2 million from $16.3 million. Management tied this step-up largely to investments in commercial build-out and public company infrastructure, arguing that these costs are necessary to support long-term scale.

Operating Expenses and Cash Burn Climb

GAAP operating expenses reached $47.7 million in Q3, including $1.5 million of nonrecurring items, and excluding one-offs and stock-based compensation rose to $36.1 million from $24.8 million. Quarterly cash burn, excluding the BioBeat investment, was described as in the mid-$20 million range, with CapEx at about $9 million and an expected annual CapEx run rate near $30 million to fund device inventory and territory growth.

Seasonality and Conversion Variability

Management cautioned that conversion rates are subject to seasonal pressures, particularly deductible resets in January and the holiday period, which can make Q3 results more volatile despite underlying improvement. Investors were reminded that such quarter-to-quarter noise is expected even as the year-over-year conversion trend remains positive.

Competitive Landscape and Payer Complexity

Kestra acknowledged that incumbent rival ZOLL has launched a larger WCD device but said it has not seen a material impact on its business to date. However, the company pointed to an intense focus on ease-of-business and the challenge of contracting with more than 3,000 U.S. payers, creating a long tail of agreements that will require sustained effort.

Execution Risks from Rapid Scale-Up

The push toward roughly 130 territories brings execution risk, as new hires must ramp productivity quickly to justify higher fixed costs. Management conceded that if the pace of sales ramp lags expectations, near-term profitability could come under additional pressure, underscoring the importance of disciplined hiring, training, and territory management.

Guidance and Path Ahead

Looking forward, Kestra’s higher fiscal 2026 revenue guidance to $93 million rests on continued prescription growth, a rising in-network mix that lifts revenue-per-fit, improving conversion rates, and the expanded sales footprint. With Q3 gross margin at 52.6% and a stated path to 70%+, management framed the current period as an investment phase funded by a strong $291 million cash position and supported by planned annual CapEx of roughly $30 million.

Kestra’s latest call painted a picture of a company moving quickly to build scale, backed by strong revenue growth, improving economics, and compelling clinical data. For investors, the story is a classic growth trade-off: promising momentum and expanding market access against higher losses, heavier capital needs, and the operational risks that come with an aggressive commercial ramp.